Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Go back to Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
AGENUS (NASDAQ: AGEN) Delayed: 6.33 -0.18 (2.76%)
Previous Close $6.51    52 Week High $7.49 
Open $6.36    52 Week Low $2.61 
Day High $6.50    P/E N/A 
Day Low $6.16    EPS $-1.10 
Volume 510,113